Medtronic stock gains as ablation registries bolster cardiac portfolio

Medtronic reported positive real-world registry findings for two cardiac ablation systems on October 22, 2026, with the results presented at the Asia Pacific Heart Rhythm Society meeting. The company's press release described data from the Affera Mapping and Ablation System with the Sphere-9 catheter and the PulseSelect pulsed field ablation system.

Registry results span major arrhythmias

The global APEX registry included 1,050 patients with atrial fibrillation treated with Sphere-9 and Affera across 28 sites. Medtronic reported a 1.1 percent major complication rate, with no acute kidney injury, severe coronary spasm or phrenic nerve injury. Results did not differ significantly between first-time and repeat ablation procedures.

The REAL PULSE registry covered 1,160 atrial fibrillation patients treated with PulseSelect at 38 sites. The company reported a 100 percent acute success rate and a 0.09 percent acute major complication rate.

A separate European APEX analysis examined Sphere-9 in 46 patients undergoing treatment for sustained ventricular tachycardia. Acute success reached 87 percent, while estimated freedom from ventricular tachycardia recurrence at six months stood at 75 percent. Six major complications occurred in four patients. Medtronic said Sphere-9 is CE marked for ventricular tachycardia but remains investigational and not approved for that indication in the United States.

Clinical evidence is not revenue guidance

The results broaden the evidence supporting Medtronic's electrophysiology portfolio, which combines high-definition mapping with pulsed field and radiofrequency ablation through Affera and offers a single-shot approach to pulmonary vein isolation through PulseSelect. For investors, the findings strengthen the cardiovascular growth narrative, while commercial adoption, reimbursement and execution remain the next key considerations.

Medtronic stock traded at 93.41 euros on Lang & Schwarz at 18:02 CET on Wednesday, November 4, 2026, 0.33 percent above the Xetra close of Wednesday, November 4, 2026.

The real-time quote of Medtronic stock provides the latest trading context.

The broader European equity market remains the relevant backdrop for investors following the Euro Stoxx 50.

More news and analyses on Medtronic stock are available in the company topic.